Carotid plaque inflammation assessed by 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and lipoprotein-associated phospholipase A2 (Lp-PLA2) levels are higher in symptomatic patients. The aim of this study was to assess correlations between 18F-FDG uptake on PET scan of carotid artery plaques, plasma levels of Lp-PLA2, and cerebrovascular symptoms. The study included 45 consecutive patients (22 symptomatic, 23 asymptomatic) with >70% carotid stenosis. Patients were examined by hybrid PET/CT, and maximum standardized uptake values (SUVmax) were recorded. Blood samples were obtained, and plasma was stored at −80 °C for subsequent Lp-PLA2 analysis. Symptomatic and asymptomatic patients showed no significant difference in classical cardiovascular risk factors. Asymptomatic carotid stenosis patients more frequently had a history of coronary artery disease (P = .025) and peripheral artery disease (P = .012). The symptomatic group had higher 18F-FDG uptake in carotid plaques (P < .001), higher plasma Lp-PLA2 (P < .01), and higher high-sensitive C-reactive protein (P = .022). 2-Deoxy-2-[18F]fluoro-D-glucose uptake on PET/CT and plasma Lp-PLA2 show a statistically significant association with the symptomatic status of carotid plaques.
LibbyP. Inflammation in Atherosclerosis. Arterioscler Throm Vasc Biol. 2012;32:2045–2051.
2.
De WeerdMGrevingJPHedbladB, et al.Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke. 2010;41:1294–1297.
3.
den HartogAGAchterbergSMollFL, et al.Asymptomatic carotid artery stenosis and the risk of ischemic stroke according to subtype in patients with clinical manifest arterial disease. Stroke. 2013;44:1002–1007.
4.
NaylorARRiccoJRde BorstGJ, et al.Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55:3–81
5.
EppsKCWilenskyRL. Lp-PLA2-a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med. 2011;269:94–106.
GraebeMBorgwardtLHøjgaardL, et al.When to image carotid plaque inflammation with FDG PET/CT. Nucl Med Commun. 2010;31:773–779.
8.
RuddJHMyersKSBansilalS, et al.(18) Fluorodeoxyglucose Positron Emission Tomography Imaging of Atherosclerotic Plaque Inflammation Is Highly Reproducible. J Am Coll Cardiol. 2007;50:892–896.
9.
TawakolAMigrinoRQBashianGG, et al.In Vivo 18 Fluorodeoxyglucose Positron Emission Tomography Imaging Provides a Noninvasive Measure of Carotid Plaque Inflammation in Patients. J Am Coll Cardiol. 2006;48:1818–1824.
10.
InzitariDEliasziwMGatesP, et al.The causes and risk of stroke in patients with asymptomatic internal carotid artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 2000;342:1693–1700.
11.
KarlssonLKangefjärdEHermanssonS, et al.Risk of Recurrent Stroke in Patients with Symptomatic Mild (20-49% NASCET) Carotid Artery Stenosis. Eur J Vasc Endovasc Surg. 2016;52:287–294.
12.
SkagenKJohnsrudKEvensenK, et al.Carotid Plaque inflammation assessed with (18)F-FDG PET/CT is higher in symptomatic compared with asymptomatic patients. Int J Stroke. 2015;10:730–736.
13.
MusialekPTraczWTekieliL, et al.Multimarker Approach in Discriminating Patients with Symptomatic and Asymptomatic Atherosclerotic Carotid Artery Stenosis. J Clin Neurol. 2013;9:165–175.
14.
ArnoldNKoenigW. Atherosklerose als inflammatorische Erkrankung—Pathophysiologie, klinische Relevanz und therapeutische Implikationen. [Atherosclerosis as an Inflammatory Disease—Pathophysiology, Clinical Relevance and Therapeutic Implications]. Dtsch Med Wochenschr. 2019;144:315–321.
15.
OwenDRLindsayACChoudhuryRP, et al.Imaging of atherosclerosis. Annu Rev Med. 2011;62:25–40.
16.
SheikineYAkramK. FDG-PET imaging of atherosclerosis: Do we know what we see?Atherosclerosis. 2010;211:371–380.
17.
RuddJHFWarburtonEAFryerTD, et al.Imaging Atherosclerotic Plaque Inflammation with [18F]-Fluorodeoxyglucose Positron Emission Tomography. Circulation. 2002;105:2708–2711.
18.
GræbeMPedersenSFHøjgaardL, et al.18FDG PET and Ultrasound Echolucency in Carotid Artery Plaques. JACC Cardiovasc Imaging. 2010;3:289–295.
19.
HermusLLefrandtJDTioRA, et al.Carotid Plaque Formation and serum biomarkers. Atherosclerosis. 2010;213:21–29.
20.
PederesenSFHagAMKlausenTL, et al.Positron emission tomography of the vulnerable atherosclerotic plaque in man—a contemporary review. Clin Physiol Funct Imaging. 2014;34:413–25.
21.
RuddJHFMyersKSBansilalS, et al.Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations. J Nucl Med. 2008;49:871–878.
22.
VeseyATJenkinsWSIrkleA, et al.18F-Fluoride and 18F-Fluorodeoxyglucose positron emission tomography after transient ischemic attack or minor stroke: case-control study. Cir Cardiovasc Imaging. 2017;10:1–10.
23.
TarkinJMJoshiFREvansNR, et al.Detection of atherosclerotic inflammation by 68Ga-DOTATATE PET compared to 18F-FDG PET Imaging. J Am Coll Cardiol. 2017;69:1774–91.
24.
BlombergBAAkersSRSabouryB, et al.Delayed time-point 18F-FDG PET CT imaging enhances assessment of atherosclerotic plaque inflammation. Nucl Med Commun2013;34:860–867.
25.
BuceriusJHyafilFVerberneH, et al.Position paper of the Cardiovascular Committee of the European Associations of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. Eur J Nucl Med Mol Imaging. 2016;43:780–792.
26.
JoshiFRManavakiRFryerTD, et al.Vascular Imaging with 18F-fluorodeoxyglucose positron emission tomography is influenced by hypoxia. J Am Coll Cardiol. 2017;69:1873–4.
27.
AmmiratiEMoroniFNorataGD, et al.Markers of Inflammation Associated with Plaque Progression and Instability in Patients with Carotid Atherosclerosis. Mediators Inflamm. 2015:718329. doi:10.1155/2015/718329
28.
TuñónJBäckMBadimónL, et al.Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. Eur J Prev Cardiol. 2018;25:948–955.
29.
PerssonMBerglundGNelsonJJ, et al.Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Mälmo, Sweden. Atherosclerosis. 2008;200:191–198.
30.
ZlewskiAMacpheeC.Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis. Biology, Epidemiology and Possible Therapeutic Target. Arterioscler Thromb Vasc Biolo. 2005;25:923–931.
31.
MadjidMAliMWillersonJT. Lipoprotein-Associated Phospholipase A2 as a Novel Risk Marker for Cardiovascular Disease. Tex Heart Inst J. 2010;37:25–39.
32.
Lp-PLA(2) Studies Collaboration; ThompsonAGaoP, et al.Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536–44.
33.
CorsonMAJonesPHDavidsonMH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008;101:41F–50F.
34.
TsimikasSWilleitJKnoflachM, et al.Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J. 2009;30:107–15.
35.
DuivenvoordenRManiVWoodwardM, et al.Relationship of Serum Inflammatory Biomarkers with Plaque Inflammation Assessed by FDG PET/CT. The dal-PLAQUE Study. JACC Cardiovasc Imaging. 2013;6:1087–94.
36.
Sarlon-BartoliGBoudesABuffatC, et al.Circulating Lipoprotein-associated Phospholipase A2 in High-grade Carotid Stenosis. A New Biomarker for Predicting Unstable Plaque. Eur J Vasc Endovasc Surg. 2012;43:154–159.
37.
PeetersWHellingsWEde KleijnDP, et al.Carotid atherosclerotic plaques stabilize after stroke: insights into the natural process of atherosclerotic plaque stabilization. Arterioscle Thromb Vasc Biol. 2009;29:128–133.
38.
BuceriusJManiVMoncrieffC, et al.Impact of Noninsulin-Dependent Type 2 Diabetes on Carotid Wall 18F-Fluorodeoxyglucose Positron Emission Tomography Uptake. J Am Coll Cardiol. 2012;59:2080–8.
AlieNEldibMFayadZAManiV.Inflammation, Atherosclerosis, and Coronary Artery Disease: PET/CT for the Evaluation of Atherosclerosis and Inflammation. Clin Med Insights Cardiol. 2015;8:13–21.
41.
FashanuOEOyenugaAOZhaoD, et al.GlycA, a Novel Inflammatory Marker and Its Association With Peripheral Arterial Disease and Carotid Plaque: The Multi-Ethnic Study of Atherosclerosis. Angiology. 2019;70:737–746.
42.
MotoyamaRSaitoKTonomuraS, et al.Utility of Complementary Magnetic Resonance Plaque Imaging and Contrast-Enhanced Ultrasound to Detect Carotid Vulnerable Plaques. J Am Heart Assoc. 2019;8:e011302.
43.
SchmidtCFischerTRückertRI, et al.Identification of neovascularization by contrast-enhanced ultrasound to detect unstable carotid stenosis. PLoS One. 2017;12:e0175331.
44.
MetzSBeerAJSettlesM, et al.Characterization of carotid artery plaques with USPIO-enhanced MRI: assessment of inflammation and vascularity as in vivo imaging biomarkers for plaque vulnerability. Int J Cardiovasc Imaging. 2011;27:901–12.
45.
SiricoGSpaderaLDe LaurentisMBrevettiG.Carotid artery disease and stroke in patients with peripheral arterial disease. The role of inflammation. Monaldi Arch Chest Dis. 2009;72:10–17.
46.
PanZWangRLiLZhangH. Correlation between significant asymptomatic carotid artery stenosis and severity of peripheral arterial occlusive disease in the lower limb: a retrospective study on 200 patients. BMC Neurol. 2019;19(1):259.
47.
ChowdhuryMMTarkinJMEvansNR, et al.18F-FDG Uptake on PET/CT Symptomatic versus Asymptomatic Disease: A Meta-Analysis. Eur J Vasc Endovasc Surg. 2018;56:172–179.
48.
MoghbelMAl-ZaghalAWernerTJ, et al.The Role of PET in Evaluating Atherosclerosis: A Critical Review. Semin Nucl Med. 2018;48:488–497.
49.
MarnaneMMerwickASheehanO, et al.Carotid Plaque Inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early Stroke Recurrence. Ann Neurol. 2012;71:709–718.
